Novartis to restructure US business to strengthen competitive position in light of loss of Diovan® patent
13 January 2012 | By Novartis
US General Medicines restructuring results in reduction of 1,960 positions...
List view / Grid view
13 January 2012 | By Novartis
US General Medicines restructuring results in reduction of 1,960 positions...
13 January 2012 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company is commencing a cash tender offer to purchase all outstanding shares of common stock of Inhibitex...
12 January 2012 | By Gilead Sciences
Following the merger, Pharmasset will become a wholly-owned subsidiary of Gilead...
12 January 2012 | By B&W Tek Inc
B&W Tek, Inc., is proud to introduce the BAC200...
12 January 2012 | By B&W Tek, Inc
In the last 15 years B&W Tek has experienced substantial growth in size, value, skills and core competencies...
IFF, a leading global creator of flavors and fragrances, uses the Syrris Atlas Calorimeter for flavor and fragrance development at its production plant in Benicarlo, Spain.
11 January 2012 | By kdm communications limited
Tecan’s Infinite® M1000 multimode microplate reader has enabled scientists to develop a high throughput system...
11 January 2012 | By GlaxoSmithKline
GlaxoSmithKline respectfully disagrees with the recent court ruling in favour of ANMAT...
11 January 2012 | By AstraZeneca
AstraZeneca has entered into a three-year collaboration agreement with IMS Health...
10 January 2012 | By Sanofi
Sanofi is co-investing in Warp Drive Bio, an innovative start-up biotechnology company...
9 January 2012 | By Citigate Dewe Rogerson
SFJ announced that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial...
9 January 2012 | By AstraZeneca
The info was out of date planning information...
9 January 2012 | By GlaxoSmithKline
GSK and Theravance, Inc. announced the completion of the phase III registration programme...
8 January 2012 | By Novartis
There have been no related adverse events reported with the issues leading to the recall...
7 January 2012 | By Bristol-Myers Squibb
Bristol-Myers Squibb to acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger...